Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zevra Therapeutics, Inc. - Common Stock
(NQ:
ZVRA
)
7.070
-0.110 (-1.53%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Zevra Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 19, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 15, 2024
Via
Benzinga
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q2 2024
August 13, 2024
ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Zevra Therapeutics Mixed Q2 Results: Details
August 13, 2024
Zevra Therapeutics reported its second-quarter financial results Tuesday. Here's a look at the details.
Via
Benzinga
Zevra Therapeutics: Q4 Earnings Insights
March 28, 2024
Via
Benzinga
Earnings Outlook For Zevra Therapeutics
March 27, 2024
Via
Benzinga
Zevra Therapeutics's Earnings: A Preview
November 06, 2023
Via
Benzinga
Zevra Therapeutics's Earnings: A Preview
August 11, 2023
Via
Benzinga
PubMatic, Eventbrite, Five9 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
August 09, 2024
Via
Benzinga
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
August 05, 2024
Via
Benzinga
FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases
August 05, 2024
FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare...
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
July 23, 2024
Via
Benzinga
A Preview Of Zevra Therapeutics's Earnings
May 12, 2023
Via
Benzinga
Insiders Buying Zevra Therapeutics And 1 Other Stock
July 18, 2024
Via
Benzinga
Insiders Buying Barnes & Noble Education And 2 Other Stocks
July 17, 2024
Via
Benzinga
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
July 09, 2024
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.
Via
Benzinga
Exposures
Product Safety
ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 08, 2024
ZVRA stock results show that Zevra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023
March 28, 2024
ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
December 28, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Earnings Scheduled For March 28, 2024
March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
Via
Benzinga
Health Care Company Zevra Therapeutics Announces Merger With Acer Therapeutics
August 31, 2023
Via
Benzinga
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Why Is Acer Therapeutics Stock Trading Higher Today?
August 31, 2023
Zevra Therapeutics Inc (NASDAQ: ZVRA) has agreed to acquire Acer Therapeutics Inc (NASDAQ: ACER) for up to $91 million.
Via
Benzinga
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
August 31, 2023
Acer Therapeutics (ACER) stock is taking off on Thursday after the company announced an acquisition deal with Zevra Therapeutics (ZVRA).
Via
InvestorPlace
Earnings Scheduled For May 15, 2023
May 15, 2023
Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.
Via
Benzinga
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Citius Pharmaceuticals Approaches End Of Trial For Catheter-Related Bloodstream Infections – How Are Analysts Scoring Its Stock?
May 04, 2023
The late-stage biopharma Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is approaching the conclusion of the phase 3 trial for its drug, Mino-Lok.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
March 17, 2023
Via
Benzinga
Over $7M Bet On This Consumer Defensive Stock? Check Out These 4 Penny Stocks Insiders Are Buying
March 16, 2023
The Dow Jones closed lower by more than 250 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 07, 2023
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.